NDC	PRODUCTTYPENAME	PROPRIETARYNAME	PROPRIETARYNAMESUFFIX	NONPROPRIETARYNAME	DOSAGEFORMNAME	ROUTENAME	STARTMARKETINGDATE	ENDMARKETINGDATE	MARKETINGCATEGORYNAME	APPLICATIONNUMBER	LABELERNAME	SUBSTANCENAME	ACTIVE_NUMERATOR_STRENGTH	ACTIVE_INGRED_UNIT	PHARM_CLASSES	DEASCHEDULE	NDC_EXCLUDE_FLAG	LISTING_RECORD_CERTIFIED_THROUGH	PRIMARY_ICD10	ALL_ICD10_MAPPINGS	MAPPING_CONFIDENCE
0002-0152	HUMAN PRESCRIPTION DRUG	Zepbound		tirzepatide	INJECTION, SOLUTION	SUBCUTANEOUS	20231108		NDA	NDA217806	Eli Lilly and Company	TIRZEPATIDE	2.5	mg/.5mL	G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]		N	20261231	E11.9	"[{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.7,""context"":""diabetes indication""},{""icd10_code"":""E66.9"",""description"":""Obesity, unspecified"",""confidence"":0.25,""context"":""weight management (Zepbound)""},{""icd10_code"":""E11.69"",""description"":""Type 2 diabetes with other specified complication"",""confidence"":0.05,""context"":""complex diabetes""}]"	0.70
0002-0213	HUMAN OTC DRUG	Humulin	R	Insulin human	INJECTION, SOLUTION	PARENTERAL	19830627		BLA	BLA018780	Eli Lilly and Company	INSULIN HUMAN	100	[iU]/mL	Insulin [CS], Insulin [EPC]		N	20251231	E11.9	"[{""icd10_code"":""E10.9"",""description"":""Type 1 diabetes mellitus without complications"",""confidence"":0.3,""context"":""insulin-dependent""},{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.6,""context"":""most common""},{""icd10_code"":""E13.9"",""description"":""Other specified diabetes mellitus without complications"",""confidence"":0.1,""context"":""secondary diabetes""}]"	0.60
0002-0243	HUMAN PRESCRIPTION DRUG	Zepbound		tirzepatide	INJECTION, SOLUTION	SUBCUTANEOUS	20231108		NDA	NDA217806	Eli Lilly and Company	TIRZEPATIDE	5	mg/.5mL	G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]		N	20261231	E11.9	"[{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.7,""context"":""diabetes indication""},{""icd10_code"":""E66.9"",""description"":""Obesity, unspecified"",""confidence"":0.25,""context"":""weight management (Zepbound)""},{""icd10_code"":""E11.69"",""description"":""Type 2 diabetes with other specified complication"",""confidence"":0.05,""context"":""complex diabetes""}]"	0.70
0002-0800	HUMAN PRESCRIPTION DRUG	Sterile Diluent		diluent	INJECTION, SOLUTION	SUBCUTANEOUS	19870710		BLA	BLA020563	Eli Lilly and Company	WATER	1	mL/mL			N	20261231	Z51.81	"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]"	0.10
0002-1152	HUMAN PRESCRIPTION DRUG	MOUNJARO		tirzepatide	INJECTION, SOLUTION	SUBCUTANEOUS	20230728		NDA	NDA215866	Eli Lilly and Company	TIRZEPATIDE	2.5	mg/.5mL	G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]		N	20261231	E11.9	"[{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.7,""context"":""diabetes indication""},{""icd10_code"":""E66.9"",""description"":""Obesity, unspecified"",""confidence"":0.25,""context"":""weight management (Zepbound)""},{""icd10_code"":""E11.69"",""description"":""Type 2 diabetes with other specified complication"",""confidence"":0.05,""context"":""complex diabetes""}]"	0.70
0002-1200	HUMAN PRESCRIPTION DRUG	Amyvid		Florbetapir F 18	INJECTION, SOLUTION	INTRAVENOUS	20120601		NDA	NDA202008	Eli Lilly and Company	FLORBETAPIR F-18	51	mCi/mL	Positron Emitting Activity [MoA], Radioactive Diagnostic Agent [EPC]		N	20251231	Z51.81	"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]"	0.10
0002-1214	HUMAN PRESCRIPTION DRUG	Zepbound		tirzepatide	INJECTION, SOLUTION	SUBCUTANEOUS	20231108		NDA	NDA217806	Eli Lilly and Company	TIRZEPATIDE	7.5	mg/.5mL	G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]		N	20261231	E11.9	"[{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.7,""context"":""diabetes indication""},{""icd10_code"":""E66.9"",""description"":""Obesity, unspecified"",""confidence"":0.25,""context"":""weight management (Zepbound)""},{""icd10_code"":""E11.69"",""description"":""Type 2 diabetes with other specified complication"",""confidence"":0.05,""context"":""complex diabetes""}]"	0.70
0002-1220	HUMAN PRESCRIPTION DRUG	TAUVID		Flortaucipir F-18	INJECTION, SOLUTION	INTRAVENOUS	20220701		NDA	NDA212123	Eli Lilly and Company	FLORTAUCIPIR F-18	100	mCi/mL			N	20251231	Z51.81	"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]"	0.10
0002-1243	HUMAN PRESCRIPTION DRUG	MOUNJARO		tirzepatide	INJECTION, SOLUTION	SUBCUTANEOUS	20230728		NDA	NDA215866	Eli Lilly and Company	TIRZEPATIDE	5	mg/.5mL	G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]		N	20261231	E11.9	"[{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.7,""context"":""diabetes indication""},{""icd10_code"":""E66.9"",""description"":""Obesity, unspecified"",""confidence"":0.25,""context"":""weight management (Zepbound)""},{""icd10_code"":""E11.69"",""description"":""Type 2 diabetes with other specified complication"",""confidence"":0.05,""context"":""complex diabetes""}]"	0.70
